Innate Pharma

🔬𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄? An Antibody-Drug Conjugate (ADC) is an innovative therapy primarily used in oncology. It combines the precision of a monoclonal antibody with the potency of a cytotoxic drug to selectively target and destroy cancer cells. 💡𝗛𝗼𝘄 𝗱𝗼𝗲𝘀 𝗶𝘁 𝘄𝗼𝗿𝗸? 1. The antibody binds to a specific antigen on the surface of the cancer cell. 2. The ADC is internalized by the cell. 3. Inside the cell, the linker is cleaved, releasing the cytotoxic drug, which kills the cancer cell. 👨⚕️𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿?  ADCs allow for the targeted delivery of powerful cytotoxic drug, significantly reducing toxicity compared to conventional chemotherapy. #InnatePharma #ADC #ImmunoOncology #Biotech #CancerTherapy

🔬 Meet Eric Vivier, Chief Scientific Officer of Innate Pharma, who will be speaker at FOCIS 2025 on June 25, during an educational session to highlight the potential of innate immunity in cancer treatment. More information on the program 👉https://lnkd.in/ecV_Ws4i #InnatePharma #FOCiS2025 #Immunotherapy #NKcell Federation of Clinical Immunology Societies (FOCIS)

June is Immunotherapy Awareness Month! 🌟 At Innate Pharma, we’re proud to be at the forefront of immunotherapy innovation, harnessing the power of the immune system to fight cancer. This month, we celebrate the incredible progress made and the teams driving change every day. Test your knowledge with our quick quiz! 🧬 #ImmunotherapyAwarenessMonth #CancerResearch #InnatePharma #InnovationInHealthcare #ImmunotherapyQuiz

We’re pleased to share that the long-term follow-up data from the TELLOMAK Phase 2 trial, recently presented at ASCO, will be featured again as an encore presentation and poster at the upcoming International Conference on Malignant Lymphoma (ICML) from June 17 to 21, in Lugano. Oral Session: 📌 Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Long term follow-up from the TELLOMAK Phase 2 Trial 🗓️ Saturday, June 21, 2025 | 10:25 - 10:35 am Presenter: Dr. Martine Bagot Poster Session: 📌 Lacutamab in patients with relapsed and/or refractory mycosis fungoides: long term follow-up and translational data from the TELLOMAK phase 2 trial First author: Dr. Youn H Kim Abstract number: 398 The poster will be on display throughout the conference. As a congress dedicated to malignant lymphoma, ICML offers an important platform to engage with specialists in the field, and we’re proud to take part to the dialogue to advance medical research for T cell Lymphomas! For more info: https://lnkd.in/d-9mNRkK #InnatePharma #Lymphoma #ICML International Conference on Malignant Lymphoma (ICML)  

#MeetInnate Come and meet members of our management team at the next IR conferences below 🚀 📍 H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference June 24, 2025 | Virtual 📍 Wolfe Research Virtual Biotech Day June 26, 2025 | Virtual More info: https://lnkd.in/dzf4NzH9 #InnatePharma #IRmeeting #InvestorRelations

🚀 Innate Pharma at #EHA2025 Our CEO, Jonathan Dickinson, met with Brad Loncar of BiotechTV during the EHA 2025 congress to discuss our latest pipeline progress and our upcoming catalysts. 🧬 A great opportunity to share how Innate Pharma is advancing science to improve patient outcomes. 📺 Watch the full interview here 👉 https://lnkd.in/gfTbWzcB #InnatePharma #ImmunoOncology #EHA2025 #Biotech #CancerResearch #Innovation

Innate Pharma highlights preclinical antitumor activity of IPH6501, Innate’s proprietary ANKET® targeting CD20, in diffuse large B-cell lymphoma and follicular lymphoma and combination potential with R-CHOP 🔬   These preclinical data will be presented at the European Hematology Association (EHA) Congress 2025, taking place from June 12 to 15 in Milan, Italy.    ➡️ These findings underscore the potential of IPH6501 in improving standard-of-care R-CHOP treatment in previously untreated Diffuse Large B-Cell Lymphoma and Follicular Lymphoma patients and support further evaluation of additional combination strategies in B-cell non-Hodgkin lymphomas.   More info in the press release: https://lnkd.in/egrBjnP3   #InnatePharma #EHA2025 #Lymphoma

#clubdesactionnaires Les dernières news d’Innate Pharma dans la lettre aux actionnaires du mois de juin 📨 📽️ Le replay de notre Assemblée Générale et les résultats de vote 📊 Les chiffres clés du 1er trimestre 2025 📣 Les présentations lors des congrès scientifiques majeurs ✅ Les réponses durables de lacutamab dans le syndrome de Sézary et le mycosis fongoïde 📚 Notre nouvelle brochure “l’Essentiel 2025” Si vous êtes actionnaires et que vous souhaitez recevoir la lettre, inscrivez vous au club Innate en actions : https://lnkd.in/eKsSHbiy #InnatePharma #Investisseur #LettreAuxActionnaires  

#MeetInnate Come and meet members of our management team at the Jefferies Global Healthcare Conference and exchange during a fireside chat being held on Thursday, June 5 at 8:10 am ET. Link to the webcast: https://lnkd.in/eRVGcC9E #InnatePharma #IRmeeting #Immunotherapy

Just back from the American Society of Clinical Oncology (ASCO) annual meeting 2025 — always a highlight of the year for the oncology community, and this edition was no exception. Thank you to everyone who stopped by, asked thoughtful questions, and contributed to such meaningful conversations. Innate Pharma was proud to take part in this year’s program with two poster sessions: 🔹We shared long-term follow-up data from our Phase 2 TELLOMAK trial in mycosis fungoides and Sézary syndrome, offering new perspectives on the durability of our approach in cutaneous T-cell lymphomas. 🔹 We also presented a Trial in Progress poster on our ongoing Phase 1 study of IPH4502, a Nectin-4–targeting ADC under investigation in advanced solid tumors. These presentations reflect our ongoing commitment to developing innovative therapies for both hematologic and solid tumors — with scientific rigor and a clear focus on unmet patient needs. The posters are available on our website! Thanks to ASCO and everyone who helped make this such an energizing and inspiring week! #ASCO2025 #Oncology #CancerResearch #ImmunoOncology #InnatePharma